Bausch Health Companies (BHC) said Tuesday its subsidiary has extended the expiration date of its tender offer to acquire all of the outstanding shares of DURECT Corporation (DRPX) till Sept. 10 from the earlier deadline of Sept. 9.

Bausch Health, during July, had announced to acquire DURECT for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million.

The company had said that this transaction bakes in with the potential for two additional net sales milestone payments of up to $350 million in the aggregate if the milestones are achieved before the earlier of the 10-year anniversary of the first commercial sale of larsucosterol in the US and December 31, 2045.